New Face on the Board: Pelthos Therapeutics Welcomes Finance Expert

Pelthos Therapeutics has recently bolstered its leadership team by adding Andrew J. Einhorn, a finance veteran with over 40 years of experience. Einhorn is stepping into significant roles, including the Audit Committee and Compensation Committee.

A Seasoned Professional

Einhorn's extensive background includes:

• Investment Banking
• Leading finance teams at biotech companies
• Consulting for Danforth Advisors
• Holding CFO positions at several biotech firms
• Over two decades in capital markets

With this addition, Pelthos' board now comprises eight members. Einhorn expressed enthusiasm about joining Pelthos, citing its strong start as a publicly traded company.

Pelthos Therapeutics: Innovating for Patients

Pelthos Therapeutics is dedicated to developing new treatments for patients in need. Their first product, ZELSUVMI, received FDA approval last year for treating molluscum contagiosum.

Future Prospects and Risks

While the company's future looks promising, several factors could impact its success:

• Market acceptance
• Regulatory approvals
• Economic conditions